𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia

✍ Scribed by Dr Federico Pea, Domenico Russo, Mariagrazia Michieli, Daniela Damiani, Renato Fanin, Angela Michelutti, Teresa Michelutti, Stefano Piccolrovazzi, Michele Baccarani, Mario Furlanut

Book ID
119926510
Publisher
Springer International Publishing AG
Year
2003
Tongue
English
Weight
157 KB
Volume
42
Category
Article
ISSN
0312-5963

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High-dose liposomal daunorubicin and hig
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
✍ Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 2 views

## Background: Liposomal encapsulation of daunorubicin (daunoxome, dnx; nexstar pharmaceutical, boulder, co) changes the pharmacology profile to increase delivery to tumor sites and decrease toxicity. the authors investigated the effect of daunorubicin in combination with ara-c in patients with ref

A randomized trial of liposomal daunorub
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
✍ Jorge Cortes; Hagop Kantarjian; Maher Albitar; Deborah Thomas; Stefan Faderl; Ch πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 102 KB

## Abstract ## BACKGROUND Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti‐angiogenic activity, this study was designed to investigate the potential role of Th in t